Legeviten > Infeksjonsmedisin
It's a new moon, and the jungle is as dark as the deep sea.
(sciencenow.sciencemag.org)
[02.06.2017 01:06]
|
Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2.
Les mer »
VL-2397 appeared safe and well-tolerated with favorable pharmokinetic profile in healthy subjects.
(www.digitalproducer.com) |
OpGen Data at ASM Microbe 2017 Demonstrates Potential of Acuitas Products for Predicting Antibiotic Susceptibility and Infection Control.
Les mer »
?These data presented at ASM Microbe 2017 further demonstrate the potential of our Acuitas products and the Acuitas Lighthouse Knowledgebase, said Evan Jones, Chairman and CEO of OpGen.
(www.digitalproducer.com) |
|
STAT-Dx: EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain.
Les mer »
EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain.
(inpublic.globenewswire.com) |
ASM Microbe: New Diagnostics, Therapies Take the Stage in the Big Easy.
Les mer »
Advances in testing, therapeutics will be clinical highlights.
(MedPage Today) |
|
Could pigs be involved in Congo's new Ebola outbreak?
Les mer »
It might all just be a big coincidence.
(sciencenow.sciencemag.org) |
|
GAO: Agencies Unprepared for Zika Outbreak.
Les mer »
House panel debates impact of proposed budget cuts to HHS, Medicaid.
(MedPage Today) |
|
A Triple Threat.
Les mer »
The mosquitoes that carry Zika may be able to transmit two other viruses at the same time.
(The Scientist) |
|
As Ebola outbreak grows, question of using vaccine becomes more urgent.
Les mer »
As health officials and aid workers head to a remote corner of the Democratic Republic of the Congo to respond to an outbreak of Ebola virus disease, a key question remains: Will the government authorize the use of a promising experimental vaccine?
(sciencenow.sciencemag.org) |
Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting.
Les mer »
- Company expects more than 10 new blockbuster products to launch or file for regulatory approval by 2021- More than 50 line-extension regulatory filings projected by 2021- Beyond 2021, early-stage pi...
(www.digitalproducer.com) |
|
NASEM Urges More U.S. Involvement in Global Health.
Les mer »
Wants White House to set up 'coordinating body' for global health emergencies.
(MedPage Today) |
Two Confirmed Cases of Ebola in Congo.
Les mer »
More than a dozen other individuals are suspected of infection in the central African nation.
(The Scientist) |
|
Vical Reports First Quarter 2017 Financial Results.
Les mer »
Vical had cash and investments of $39.2 million at March 31, 2017. The Companys net cash burn for the first quarter of 2017 was $1.8 million, which was consistent with the Companys full year guidance of between $8 million and $11 million.
(www.digitalproducer.com) |
This Week in Zika: Testing Info Lacking on Texas Health Dept. Sites.
Les mer »
Also: animal research on effect of Zika infection during infancy.
(MedPage Today) |
|
Drug-Resistant TB on the Rise in These Four Counties.
Les mer »
One-third of Russian cases in 2040 expected to resist multiple drugs.
(MedPage Today) |
Drug-resistant tuberculosis strains gain foothold.
Les mer »
Russia’s daunting number of new cases of multidrug-resistant tuberculosis may be on the rise.
(sciencenow.sciencemag.org) |
|
Antibiotics Knock Out Lyme in Kids.
Les mer »
Review finds most Lyme symptoms resolved within 6 months of starting therapy.
(MedPage Today) |
|
Systemic Tx Offers Better Outcomes in Severe Uveitis.
Les mer »
Earn Free CME Credits by reading the latest medical news in your specialty.
(MedPage Today) |
Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases.
Les mer »
LANCET INFECTIOUS DISEASES WITH DATA SHOWING SUMMIT'S RIDINILAZOLE ACHIEVED STATISTICAL SUPERIORITY OVER VANCOMYCIN IN THE TREATMENT OF C. DIFFICILE INFECTION.
(inpublic.globenewswire.com) |
|
Human vaccine data release jump-starts biotech’s bid for RNA drugs.
Les mer »
their first early snapshot of human efficacy data that demonstrate their messenger RNA tech works — at least on the first try.
(sciencenow.sciencemag.org) |
Zika Virus Persists in the Nervous System and Elsewhere.
Les mer »
Studies of infected rhesus monkeys reveal the virus’s long-term hiding places in the body.
(The Scientist) |
|
Q&A: First U.S. state-by-state analysis of hepatitis C cases.
Les mer »
In the infectious disease world, the liver-damaging hepatitis C virus long has lived in the shadows of killers such as HIV/AIDS, tuberculosis, and malaria.
(sciencenow.sciencemag.org) |
Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS Lead Anti-infective Candidate SCY-078.
Les mer »
Presentations support SCY-078's potential as a novel treatment for .
(www.digitalproducer.com) |
|
Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy.
Les mer »
RICHMOND, Calif.
(www.digitalproducer.com) |
Dispatches from the Front Lines: CDC's Disease Detective Conference.
Les mer »
Epidemic Intelligence Service officers tackle top public health threats.
(www.digitalproducer.com) |
|
DNA-vaksine skal stoppe det fryktede zikaviruset.
Les mer »
Amerikanske helsemyndigheter går nye veier.
(Teknisk Ukeblad) |
|
SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID.
Les mer »
Mahmoud Ghannoum, Ph.D., Professor and Director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
(www.digitalproducer.com) |
|
STAT-Dx Unveils New In-Vitro Diagnostic System DiagCORE®.
Les mer »
Fully-Integrated, Molecular Diagnostics System Unveiled at ECCMID.
(inpublic.globenewswire.com) |
Immune Design Announces Presentations at the 2017 ASCO Annual Meeting.
Les mer »
Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas.
(www.digitalproducer.com) |
|
Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017.
Les mer »
- E-poster EV0435: Patients tolerate switch from IV to oral antibiotics in acute bacterial skin and skin structure Infections earlier than European physicians may predict.
(www.digitalproducer.com) |
|Om Viddi.no | Kontakt oss på support (a) viddi.no | Copyright® - 2006 Viddinews AS |